Roswell Park Comprehensive Cancer Center Section 203 Budget Filing

Fiscal Year 2025 - 2026 PROPOSED



January 31, 2025

Public Authority Relationship with Unit of Government

203.6(a)

Roswell Park Comprehensive Cancer Center


The institute was founded in 1898 and became a State Institute in 1911. In 1971, it was one of the first three institutions certified as a comprehensive cancer center by the National Cancer Institute. As such, it is committed to combat cancer through basic research, clinical research and treatment, and professional and public education. Presently, there are 57 such centers designated in the United States. The institute is a 157 licensed bed facility and an ambulatory care center containing 15 multidisciplinary care centers with a staff of over 3,700 members, including clinical staff physicians, residents, fellows, and research staff. The primary physical plant covers several city blocks in downtown Buffalo.

The operation of the Institute transferred from the New York Department of Health to the RPCI Corporation on January 1, 1999. In order to meet the demands of the changing health care marketplace and to promote the strengths and capabilities of the Institute, Chapter 5 of the Laws of 1997 added a new Title 4 to Article 10-c of the Public Authorities Law authorizing the RPCI Corporation. This legislative authorization was intended to change the Institute's governance structure to afford it market and managerial flexibility. Among the special powers granted by the legislation to the Corporation were the powers to contract with the State to operate, manage, superintend and control the Institute, and to establish, collect, and adjust fees, rental and other charges in connection with the operation of the Institute.

Pursuant to subdivision 2 of Section 403 of the Public Health Law, added by such chapter, the Department of Health, acting on behalf of the State, entered into an Operating Agreement with RPCI Corporation pursuant to which operating responsibility for the Institute was transferred to RPCI Corporation effective January 1, 1999, and giving RPCI Corporation substantial independence operating the Institute, including the power to establish operating budgets, to establish and implement strategic business plans, to create subsidiary and affiliated entities, to enter into affiliations and alliances with other health care providers and to establish, collect and adjust fees, rentals and other charges in connection with the operation of the Institute. Revenues generated by the Corporation as a result of operating the Institute are considered to be revenues of the State for the purpose of its bond payment, and are required to be deposited into the Roswell Park Cancer Institute Debt Service Account of the Health Income Fund for payment of debt service on the Bonds. The Department of Health retains responsibility for paying debt service on the Bonds. After allowing for accumulation of a debt service reserve for the Institute, the remaining revenues are transferred to Roswell Park Cancer Institute Income Account of the Health Income Fund. After allowing for a balance for refunds these revenues are, in turn, transferred to RPCI Corporation.

RPCI Corporation's responsibility is to ensure the fiscal and programmatic integrity of the facility. To achieve this objective, the Corporation has updated the strategic plan for the Institute which includes major programmatic and scientific, as well as, fiscal goals. Some of the key goals include the recruitment of top tier clinical and scientific talent; developing a methodology to monitor the effectiveness of programs and faculty; enhancing financial viability through revenue and expense controls; building a strong and profitable biotechnology transfer program in collaboration with peer facilities; emphasis on clinical and translational research; as well as developing and implementing new clinical trials and establishing a cancer disease management and clinical outcomes program.

The Institute is a formally designated unit of the Graduate School of the University of New York at Buffalo and has numerous affiliation agreements with other educational institutions and hospitals. Training provided by the Institute under these arrangements includes medical, nursing and medical research.



- Revenue assumptions:
 - Base volumes

Admits 0.2%Days 0.3%

Outpatient Visits 6.4%

- Rate assumptions
 - Payer rates as negotiated
 - Governmental payer rates per regulations
- Sources of revenues:
 - Includes private and governmental contracts, grants and donations, and funding from New York State
- Staffing:
 - At current levels, adjusted for productivity standards, new initiatives, strategic research initiatives and infrastructure
- Future collective bargaining costs:
 - Bargaining unit increases for FY26 include Step and COLA per negotiated contracts

Inflation:

- Salaries Steps and COLA factored in as previously noted
- Fringe Benefits increased consistent with salaries
- Pharmaceuticals (inflation, utilization, new therapies) = 14%
- Medical supplies, office supplies, purchased services = 3.0%; Blood supplies = 3.5%

Programmatic Goals:

- Continued expansion of local community presence
- Implementation of Roswell Park's strategic plan, including
 - Expand adoptive cellular therapy as new treatments options become available for patients
 - Expand access to Roswell Park through WNY and statewide collaborative opportunities
 - Structure an innovative cancer program to deliver transformational science, including Immunotherapy and personalized medicine
- Implementation of strategic research initiatives
- Expand capabilities for commercializing Roswell Park innovations
- Significant capital investment to upgrade existing IT systems, expand capacity and maintain currency for clinical technology

203.6(d)

- Labor/Workforce Instability
 - Recruitment and retention
 - Rising employment costs
- Durable/Sustained Inflation
- Drug Reimbursement
- Continued Uncertainty of Federal Budget
 - NCI Funding
 - Medicare & Medicaid reimbursement
 - DSH funding
- Managed Care
 - Increasing role of national insurance companies for commercial and Medicare Advantage plans
 - Increasing use of limited and tiered networks and ACO's
 - Benefit designs continue to require higher cost share (copays/coinsurance/deductible) for patients for certain services

Budgeted Revenues, Expenditures and Changes in Current Net Assets (in 000's)

203.6(e)/203.6(g)

REVENUE & FUNDING SOURCES		Last Year (Actual) FY24		urrent Year Estimated) FY25		Proposed Budget FY26	ı	Proposed FY27		Proposed FY28	Proposed FY29
Operating Revenues											
Charges for Services	\$	1,043,842	\$	1,141,661	\$	1,264,353	\$	1,389,649	\$	1,488,895	1,574,284
Other Operating revenues		31,933		27,627		27,714		31,107		30,920	30,832
Non-operating Revenues											
Investment earnings		19,453		23,120		14,663		16,912		18,365	18,666
State subsidies/grants		106,767		110,767		112,767		106,767		106,767	106,767
Federal subsidies/grants		1,157		_		_		_		_	_
Proceeds from the issuance of debt		_		_		130,000		_		_	_
Total Revenues and Funding Sources	\$	1,203,152	\$	1,303,175	\$	1,549,497	\$	1,544,435	\$	1,644,947	1,730,549
<u>EXPENDITURES</u>											
Operating expenditures											
Salaries and Wages	\$	419,870	\$	448,951	\$	493,269	\$	513,452	\$	537,637	564,123
Other Employee Benefits		120,363		139,925		157,028		166,644		177,460	189,674
Professional Services and Contracts		148,812		166,685		164,774		166,583		182,865	189,120
Supplies and Materials		472,721		533,918		593,018		645,754		695,939	736,940
Other operating expenditures		6,839		8,659		10,732		11,485		12,103	12,499
Non-operating expenditures											
Payment of principal on bonds and financing		40.744		44.000		04.704		5.050		5.004	5.000
arrangements		16,744		14,202		24,721		5,359		5,634	5,923
Interest and other fiscal charges on debt		2,852		2,209		5,734		9,236		8,595	7,872
Capital asset outlay		103,105		64,896		75,095		54,066		64,565	56,798
Total Expenditures	\$	1,291,307	\$	1,379,445	\$	1,524,371	\$	1,572,578	\$	1,684,798	1,762,948
Capital Contributions		9,428		9,700		17,809		25,765		_	250
"Excess (deficiency) of revenues and capital contributions	•	(78,727)	• ¢	(66,570)	¢	42,935	<u> </u>	(2,379)	¢	(39,851) \$	(32,150)
over expenditures"	<u>\$</u>	(10,121)	Ψ	(00,370)	Ψ	42,933	Ψ	(2,379)	Ψ	(33,031) 4	(32,130)

Cash Flow Projections (in millions)

203.5(h)

	Projected		Budgeted	udgeted Budgeted		Budgeted
		FY25	FY26	FY27	FY28	FY29
Excess/(Deficiency) of revenues and capital contributions over expenditures	\$	(66.6)	\$ 42.9	\$ (2.4)	\$ (39.9)	\$ (32.1)
Other Changes in Unrestricted Cash		(47.6)	20.0	(17.7)	(36.6)	(10.0)
Cash Impact from Operations	\$	(114.1)	\$ 63.0	\$ (20.0)	\$ (76.5)	\$ (42.2)

Projected Operating Revenues -- Net Patient Service Revenue (Charges for Services) (in 000's)

203.5(d)

	FY25	FY26	FY27	FY28	FY29	
	Projected	Budget Budget		Budget	Budget	
Volume Statistics						
Admits	6,082	6,093	6,614	6,719	6,825	
Days	46,394	46,554	49,978	50,776	51,575	
Visits	326,926	347,949	361,949	371,539	376,468	
Direct Patient Service Revenue						
RPCI IP Revenue	\$ 285,216 \$	303,962 \$	337,167 \$	354,218 \$	373,526	
RPCI OP Revenue	704,848	798,339	878,681	951,743	1,012,693	
Other	 78,776	88,008	89,510	91,105	92,741	
RPCI Total	\$ 1,068,840 \$	1,190,309 \$	1,305,358 \$	1,397,066 \$	1,478,960	
CPP IP Revenue	\$ 24,770 \$	25,203 \$	27,902 \$	29,225 \$	30,850	
CPP OP Revenue	66,281	71,852	77,086	81,687	85,734	
CPP Total	\$ 91,051 \$	97,055 \$	104,988 \$	110,912 \$	116,583	
Total Direct Patient Service Revenue	\$ 1,159,891 \$	1,287,364 \$	1,410,346 \$	1,507,978 \$	1,595,543	
Other RPCI Patient Service Revenue	\$ 5,809 \$	(2,609) \$	(2,725) \$	(2,843) \$	(4,163	
Other CPP Patient Service Revenue	 670	725	725	725	725	
Total Other Patient Service Revenue	\$ 6,479 \$	(1,884) \$	(2,000) \$	(2,118) \$	(3,438	
Total Net Patient Service Revenue	\$ 1,166,370 \$	1,285,480 \$	1,408,346 \$	1,505,860 \$	1,592,105	
RPCI Provision for Bad Debts	\$ 24,813 \$	23,538 \$	21,191 \$	19,575 \$	20,561	
CPP Provision for Bad Debts	 2,276	1,213	1,312	1,386	1,457	
Total Provision for Bad Debts	\$ 27,089 \$	24,751 \$	22,503 \$	20,961 \$	22,018	
Total Net Patient Service Revenue Net of Provision for Bad Debt	\$ 1,139,281 \$	1,260,729 \$	1,385,843 \$	1,484,899 \$	1,570,087	
Grants and Contracts	2,381	3,625	3,806	3,996	4,196	
Total Charges for Services	\$ 1,141,661 \$	1,264,353 \$	1,389,649 \$	1,488,895 \$	1,574,284	

Projected Operating Revenues — Other Operating Revenue (in 000's)

203.5(d)

		FY25	FY26	FY27	FY28	FY29
(in thousands)	Projected		Budget	Budget	Budget	Budget
Cafeteria	\$	1,755 \$	1,773 \$	1,791 \$	1,809 \$	1,827
Parking		2,900	2,900	2,929	2,958	2,988
Rebates (VHA)		3,000	3,000	3,030	3,060	3,091
Other Operating Revenues (PC's/JV's)		9,211	8,296	8,335	8,374	8,414
Network Affiliations, Agreements & Partnerships		4,051	5,172	5,244	5,317	5,391
LSB - UB Reimbursement		1,200	1,200	1,212	1,224	1,236
New Programs funded through Alliance		2,048	2,073	3,053	2,713	2,282
WNY Partnership/Rest of NY Initiatives		2,169	2,566	2,591	2,617	2,643
State Funding (ESD)		_	_	1,986	2,085	2,189
All Other		1,292	733	936	762	771
Projected Operating Revenues	\$	27,627 \$	27,714 \$	31,107 \$	30,920 \$	30,832

Salary & Fringe and Non Personnel Service Operating Expense (in 000's)

203.5(e)/203.5(f)

		FY25 Projected	FY26 Budget	FY27 Budget	FY28 Budget	FY29 Budget
<u>Salaries</u>		•	<u> </u>	<u> </u>	<u> </u>	
Salaries and Wage Costs	\$	448,951 \$	493,269	\$ 513,452 \$	537,637 \$	564,123
TOTAL Personnel Service Expense	\$	448,951 \$	493,269	\$ 513,452 \$	537,637 \$	564,123
Fringe	¢.	20 200 ¢	46.260	ф 47.77C ф	40 F70 . ¢	E4 000
NYS Pension Expense & TIAA CREF Health Insurance: Active	\$	39,200 \$ 40,043	46,268 3 44,363	\$ 47,776 \$ 48,799	49,570 \$ 53,679	51,908 59,047
Health Insurance: OPEB Payments		17,582	18,988	20,507	22,148	23,920
Other Fringe		43,100	47,409	49,561	52,062	54,799
TOTAL Fringe Expense	\$	139,925 \$	157,028	\$ 166,644 \$	177,460 \$	189,674

Note: The fringe expense includes the cash payments for NYS Pension & OPEB, but does not include the accrued cost.

Non Personnel Service Operating Expense

Professional Services & Contracts	\$ 166,685	\$ 164,774	\$ 166,583	\$ 182,865 \$	189,120
Pharmaceuticals	\$ 430,236	\$ 488,511	\$ 534,586	\$ 578,954 \$	615,135
Medical, Blood, Other Supplies	103,682	104,507	111,168	116,985	121,805
Supplies & Materials	\$ 533,918	\$ 593,018	\$ 645,754	\$ 695,939 \$	736,940
Other Operating Expenditures	\$ 8,659	\$ 10,732	\$ 11,485	\$ 12,103 \$	12,499
TOTAL Non Personnel Service Expense	\$ 709,262	\$ 768,524	\$ 823,822	\$ 890,907 \$	938,559

Reconciliation FY25 Budget to FY25 Projected (in millions)

203.6(f)

	(in millions)		
Excess (Deficiency) Revenues over Expenses (FY25 Budget)	\$	(87.2)	
Clinical Margin (volume driven)		10.8	
OPEB Cash Payment		(1.2)	
Pension Cash Payment		(2.1)	
Third Party Revenue (Medicare ICR Settlement/HCRA)		5.9	
Timing of Capital & Strategic Investments		8.5	
All Other		(1.3)	
Excess (Deficiency) Revenues over Expenses (FY25 Projected)	\$	(66.6)	

Functional Classification	Total # Employees	Total # Full Time	Total # FTE's
Clinical / Clinical Research / Academic	2,682	2,363	2,484
Scientific / Academic	245	216	227
Administrative and Other	877	772	812
Total All Functional Areas	3,804	3,352	3,523

Sources of Funding:

The Source of funding for the projected workforce is:

Patient Service Revenues - Government and Private Payers

Grants and Contracts

Donations

New York State Funding

(\$ in Millions)

As part of the Institute's long range strategic plan, investments are being made in clinical operations. These investments are critical to meeting the projected demand for oncology services and expanding access to Roswell Park's services.

Revenue Enhancements and Cost Reduction Initiatives:

Clinical Growth	\$12.1M
Margin Optimization Initiatives	\$2.5M

FY2025 to FY2029 Material Non-Recurring Resources

203.6(j)

The Institute is projecting non-recurring capital contribution revenues of approximately \$9.7M in FY25, \$17.8M in FY26, \$25.8M in FY27, \$0.0M in FY28 and \$0.3M in FY29. These contributions are expected to assist in funding the continued growth at Roswell Park.

FY26 Material Shift in Resources Between Years

203.6(k)

Capital Projects and Strategic Investments can span multiple years. These projects are approved prior to initiation, and due to the magnitude of certain projects there can be an approved balance to carry forward to the next fiscal year. Carry over balances are determined and approved by executive leadership as part of the planning process for the next fiscal year.

203.5(g)/203.6(l)

in 000's

\$4,412

PBC revenues are pledged to repayment of the following DASNY indebtedness issued through New York State Department of Health

	in Millions									
	Pro	posed								
	Bı	ıdget	F	Projection	Projec	ction	Project	tion		
Borrowed Debt Outstanding	FY26			FY27	FY28		FY29			
1 DASNY Debt issuance 7/13/2011	-									
2 DASNY Debt issuance 10/21/2016										
3 Capital lease obligations										
Debt outstanding at March 31st year end	\$	15.8	\$	14.3	\$	12.7	\$	11.0		

		Bond	Capital Leases		
Scheduled Debt Service Payment	F	Principal	Interest	Principal	Interest
For the Year ending March 31	-				
2025	\$	14,202	\$1,490	\$53 \$	147
2026		13,204	817	61	145
2027		1,432	451	69	143
2028		1,504	378	78	141
2029		1,581	301	88	138
2030-2034		4,145	839	597	635
Thereafter		2,855	136	3,406	892

\$38,923

2,240

\$4,352 \$

^{*}All debt is issued. There is currently no proposed debt.

PBC revenues are pledged to repayment of the following DASNY indebtedness issued through New York State Department of Health:

On July 13, 2011, DASNY issued debt in the amount of \$48,180,000 (RPCI allocated 74.85%). Under the terms of issuance interest ranges from 2.0% to 5.0% per annum with interest and principal payments due through 2037. The bond proceeds were used solely to defease a portion of the outstanding 1998 bond series.

On October 21, 2016, DASNY issued debt in the amount of \$144,810,000 (RPCI allocated 80.76%). Under the terms of issuance interest ranges from 3.0% to 5.0% per annum with interest and principal payments due through 2037. The bond proceeds were used solely to defease a portion of the outstanding 2003, 2004-1, 2004-2 and 2005 bond series.

On June 1, 2012, RPCIC entered into a capital lease obligation to rent 226 parking spaces for a 35 year period. Under terms of the agreement, the cost of capital is estimated at 3.4% per annum with interest and principal payments due through 2047.

Debt Service/Pledged Revenue and Debt Limited Levels (in 000's)

203.5(g)/203.6(l)

				Debt Service
	De	ebt Service	Pledged	Percent of
Debt Service as a percentage of Pledged Revenues*		FY26	Revenues	Pledged Revenues
1 DASNY Debt issuance 7/13/11	\$	— \$	1,123,410	0.0%
2 DASNY Debt issuance 10/21/16	\$	8,135 \$	1,123,410	0.7%
Total	\$	8,135		0.7%

^{*}Pledged revenues are defined in accordance with RPCI bond documents

Capital Summary (in 000's)

	FY26 Budget	
Facilities and Infrastructure	\$	24,246
Clinical, Scientific & Administrative Equipment		32,595
Information Technology		18,254
Total Capital Expenditures	\$	75,095

CERTIFICATION

By checking this box, I certify that the OSC Budget Request (Part 203) submission is complete and to the best of my knowledge and belief after reasonable inquiry, the information provided in this submission is accurate and correct. This information has been presented to and accepted by the authority's board.

Chief Financial Officer
Roswell Park Cancer Institute Corporation

Presented to The Roswell Park Board of Directors on March 26, 2025 Approved by the Board of Director's on March 26, 2025